EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-center, open label, naturalistic study of mirtazapine orally disintegrating tablets in depressed nursing home patients



Multi-center, open label, naturalistic study of mirtazapine orally disintegrating tablets in depressed nursing home patients



Pharmacotherapy 22(10): 1342, October




(PDF 0-2 workdays service: $29.90)

Accession: 035349008

Download citation: RISBibTeXText



Related references

Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Current Medical Research and Opinion 19(8): 737-746, 2003

Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania. Medicina 45(10): 778-784, 2010

Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. International Journal of Geriatric Psychiatry 21(9): 898-901, 2006

Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?. International Journal of Geriatric Psychiatry 22(10): 999-1003, 2007

Mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age. Pharmacotherapy 22(10): 1369, October, 2002

Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacology Bulletin 40(1): 47-56, 2007

A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clinical Therapeutics 27(1): 58-63, 2005

Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clinical Drug Investigation 21(6): 437-442, 2001

Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World Journal of Biological Psychiatry 10(4 Pt 3): 741-745, 2010

Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo. Advances in Clinical and Experimental Medicine 27(2): 153-158, 2018

Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World Journal of Biological Psychiatry 8(2): 112-122, 2007

Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Human Psychopharmacology 23(3): 211-216, 2008

Sexual function of patients with major depression treated with mirtazapine orally disintegrating tablets or sertraline. Journal of Affective Disorders 78(Supplement 1): S114-S115, March, 2004

An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. Clinical Drug Investigation 28(2): 113-120, 2008

Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets. Human Psychopharmacology 22(5): 307-314, 2007